Tag: lateRecurrence

News

12/07/21

Breast cancer characteristics that increase likelihood of late recurrence

11/18/17

Late recurrence of ER+ BC linked to primary tumor characteristics

10/18/15

Late recurrence of ER+ breast cancer is more likely for some women

12/09/12

Tamoxifen treatment for 10 years helps prevent late recurrence

10/21/11

Radiotherapy after lumpectomy reduces long-term recurrence

Studies

• Age and Late Recurrence in Young Patients With ER–Positive, ERBB2-Negative Breast Cancer Cite
  Shin DS, Lee J, Kang E, Noh D, Cheun J, Lee J, et al. Age and Late Recurrence in Young Patients With ER–Positive, ERBB2-Negative Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2024; 7:e2442663 10.1001/jamanetworkopen.2024.42663
• Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy Cite
  Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, et al. Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07509-1
• Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials Cite
  Foldi J, Carleton N, Anderson SJ, Rastogi P, Lee A, Balic M, et al. Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae188
• Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study Cite
  Chua AV, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, et al. Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 116:1621-1631 10.1093/jnci/djae128
• Cancer treatments as paradoxical catalysts of tumor awakening in the lung Cite
  Nicolas E, Kosmider B, Cukierman E, Borghaei H, Golemis EA, Borriello L. Cancer treatments as paradoxical catalysts of tumor awakening in the lung. Cancer and Metastasis Reviews. Springer Science and Business Media LLC; 2024; 10.1007/s10555-024-10196-5
• Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study Cite
  Chua AV, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, et al. Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae128
• Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients Cite
  Richman J, Schuster G, Buus R, Lopez-Knowles E, Dowsett M. Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07311-z
• Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy Cite
  Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, et al. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 30:5999-6006 10.1245/s10434-023-13881-x
• Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape Cite
  Ganesan R, Bhasin SS, Bakhtiary M, Krishnan U, Cheemarla NR, Thomas BE, et al. Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape. PLOS Biology. Public Library of Science (PLoS); 2023; 21:e3002275 10.1371/journal.pbio.3002275
• ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast Cite
  Rothschild HT, Mukhtar RA. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13909-2
• Predictive biological factors for late survival in patients with HER2-positive breast cancer Cite
  Kang Y, Oh SJ, Bae SY, Kim E, Lee Y, Park EH, et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2023; 13 10.1038/s41598-023-38200-y
• Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial Cite
  Zhang X, Gunda A, Kranenbarg EM, Liefers G, Savitha BA, Shrivastava P, et al. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01643-2
• Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians Cite
  Ruggieri L, Moretti A, Berardi R, Cona MS, Dalu D, Villa C, et al. Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians. International Journal of Molecular Sciences. MDPI AG; 2023; 24:4974 10.3390/ijms24054974
• Escape from breast tumor dormancy: The convergence of obesity and menopause Cite
  Roy R, Yang J, Shimura T, Merritt L, Alluin J, Man E, et al. Escape from breast tumor dormancy: The convergence of obesity and menopause. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2022; 119 10.1073/pnas.2204758119
• Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool Cite
  Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, et al. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. European Journal of Cancer. Elsevier BV; 2022; 173:20-29 10.1016/j.ejca.2022.06.029
• Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease? Cite
  Kamata A, Hino K, Kamiyama K, Takasaka Y. Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?. Cureus. Cureus, Inc.; 2022; 10.7759/cureus.22804
• Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches Cite
  Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, et al. Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Frontiers in Oncology. Frontiers Media SA; 2022; 11 10.3389/fonc.2021.667397
• Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer Cite
  Calip GS, Nabulsi NA, Hubbard C, Asfaw AA, Lee I, Zhou J, et al. Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2022; 10.1007/s10552-022-01561-2
• Mortality After Late Breast Cancer Recurrence in Denmark Cite
  Pedersen RN, Mellemkjær L, Ejlertsen B, Nørgaard M, Cronin-Fenton DP. Mortality After Late Breast Cancer Recurrence in Denmark. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.02062
• Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer Cite
  Gomez Marti JL, Brufsky A, Wells A, Jiang X. Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer. Cancers. MDPI AG; 2022; 14:253 10.3390/cancers14010253
• The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis Cite
  Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab202
• The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy Cite
  Vrieling C, Assele SY, Moser L, Sauvé N, Litière S, Fourquet A, et al. The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. European Journal of Cancer. Elsevier BV; 2021; 155:28-37 10.1016/j.ejca.2021.06.018
• Breast cancer in young women: Imaging and clinical course Cite
  Langman EL, Kuzmiak CM, Brader R, Thomas SM, Alexander SL, Lee SS, et al. Breast cancer in young women: Imaging and clinical course. The Breast Journal. Wiley; 2021; 10.1111/tbj.14261
• Time to Completion of Breast Cancer Treatment and Survival Cite
  Pratt D, Burneikis T, Tu C, Grobmyer S. Time to Completion of Breast Cancer Treatment and Survival. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10116-9
• Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression Cite
  Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis & Therapy. Springer Science and Business Media LLC; 2021; 10.1007/s40291-021-00525-7
• Factors associated with late risks of breast cancer-specific mortality in the SEER registry Cite
  Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, et al. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06233-4
• Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer Cite
  Jung EJ, Kim J, Kim J, Lee HS, Kwag S, Park J, et al. Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer. Medicine. Ovid Technologies (Wolters Kluwer Health); 2021; 100:e25000 10.1097/md.0000000000025000
• Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry Cite
  Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, et al. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06121-x
• Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy Cite
  Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AM, et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell. Elsevier BV; 2021; 184:226-242.e21 10.1016/j.cell.2020.11.018
• Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial Cite
  Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, et al. Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 10.1158/1078-0432.ccr-20-0126
• Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence Cite
  Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1234-9
• Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 Cite
  Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, et al. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:3425-3435 10.1200/jco.19.00443
• BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis Cite
  Vernaci G, Dieci MV, Manfrin S, Mantiero M, Falci C, Faggioni G, et al. BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. The Breast. Elsevier BV; 2019; 47:77-84 10.1016/j.breast.2019.07.003
• Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools Cite
  Foldi J, O’Meara T, Marczyk M, Sanft T, Silber A, Pusztai L. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:1365-1369 10.1200/jco.18.01933
• Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial Cite
  Ekholm M, Bendahl P, Fernö M, Nordenskjöld B, Stål O, Rydén L. Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial. European Journal of Cancer. Elsevier BV; 2019; 110:53-61 10.1016/j.ejca.2018.12.034
• Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer Cite
  Sparano J, O’Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, et al. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2018; 4:1700 10.1001/jamaoncol.2018.2574
• Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database Cite
  Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:209-216 10.1007/s10549-018-4968-7
• Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity Cite
  Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. British Journal of Cancer. Springer Science and Business Media LLC; 2017; 118:17-23 10.1038/bjc.2017.379
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Cite
  Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:1836-1846 10.1056/nejmoa1701830
• Fifty-Year-Follow-up Results Compared with Shorter Follow-up of Breast Cancer Patients Undergoing Radical Mastectomy with or without Adjuvant Radiotherapy Cite
  Yoshida Y, Obayasi H, Maetani S. Fifty-Year-Follow-up Results Compared with Shorter Follow-up of Breast Cancer Patients Undergoing Radical Mastectomy with or without Adjuvant Radiotherapy. Advances in Breast Cancer Research. Scientific Research Publishing, Inc.; 2017; 06:81-91 10.4236/abcr.2017.63007
• Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice Cite
  Lim YJ, Lee S, Choi N, Kwon J, Eom K, Kang E, et al. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:555-563 10.1007/s10549-017-4206-8
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype Cite
  Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1049-1060 10.1200/jco.2015.63.1010
• Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy Cite
  Li J, Jiang Y, Liu Y, Shao Z. Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. The Breast. Elsevier BV; 2017; 31:173-180 10.1016/j.breast.2016.11.008
• No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011 Cite
  Woods L, Morris M, Rachet B. No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011. Annals of Oncology. Elsevier BV; 2016; 27:2025-2031 10.1093/annonc/mdw408
• Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Cite
  Lee E, Han W, Kim MK, Kim J, Yoo T, Lee MH, et al. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2423-x
• Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients Cite
  Laurberg T, Lyngholm CD, Christiansen P, Alsner J, Overgaard J. Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. Radiotherapy and Oncology. Elsevier BV; 2016; 120:98-106 10.1016/j.radonc.2016.05.006
• Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14 Cite
  Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, et al. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2350-2358 10.1200/jco.2015.62.6630
• Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis Cite
  Zhou JZ, Riquelme MA, Gu S, Kar R, Gao X, Sun L, et al. Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. Oncogene. Springer Science and Business Media LLC; 2016; 35:5597-5607 10.1038/onc.2016.101
• Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V Cite
  Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:927-935 10.1200/jco.2015.62.3504
• Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer Cite
  Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2015; 23:830-843 10.1007/s12282-015-0649-0
• Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy Cite
  Baulies S, Belin L, Mallon P, Senechal C, Pierga J, Cottu P, et al. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. British Journal of Cancer. Springer Science and Business Media LLC; 2015; 113:30-36 10.1038/bjc.2015.174
• Markers for the identification of late breast cancer recurrence Cite
  Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0516-0
• Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics Cite
  Colzani E, Johansson ALV, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. British Journal of Cancer. Springer Science and Business Media LLC; 2014; 110:1378-1384 10.1038/bjc.2014.5
• Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer Cite
  Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2013; 19:6389-6397 10.1158/1078-0432.ccr-13-0838
• Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands Cite
  Janssen-Heijnen M, van Steenbergen L, Voogd A, Tjan-Heijnen V, Nijhuis P, Poortmans P, et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Annals of Oncology. Elsevier BV; 2014; 25:64-68 10.1093/annonc/mdt424
• Comparison of Five Different Scores for the Prediction of Late Recurrence for Oestrogen Receptor-Positive Breast Cancer Cite
  Sestak I, Dowsett M, Sgroi D, Erlander M, Ferree S, Cowens J, et al. Comparison of Five Different Scores for the Prediction of Late Recurrence for Oestrogen Receptor-Positive Breast Cancer. Annals of Oncology. Elsevier BV; 2013; 24:iii29 10.1093/annonc/mdt084.2
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Cite
  Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. Elsevier BV; 2013; 381:805-816 10.1016/s0140-6736(12)61963-1
• Tumour characteristics among women with very low-risk breast cancer Cite
  Narod SA, Valentini A, Nofech-Mozes S, Sun P, Hanna W. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:1241-1246 10.1007/s10549-012-2065-x
• Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group Cite
  Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:722-728 10.1200/jco.2011.36.8993
• Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer Cite
  Burstein HJ, Griggs JJ. Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:684-686 10.1200/jco.2011.40.1455
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet. Elsevier BV; 2011; 378:771-784 10.1016/s0140-6736(11)60993-8
• Biologic markers determine both the risk and the timing of recurrence in breast cancer Cite
  Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:607-616 10.1007/s10549-011-1564-5
• Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer Cite
  Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, et al. Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1657-1663 10.1200/jco.2010.32.2933
• Effect of Obesity on Prognosis After Early-Stage Breast Cancer Cite
  Ewertz M, Jensen M, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of Obesity on Prognosis After Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:25-31 10.1200/jco.2010.29.7614
• Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10years in early stage breast cancer Cite
  Tanis E, van de Velde C, Bartelink H, van de Vijver M, Putter H, van der Hage J. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10years in early stage breast cancer. European Journal of Cancer. Elsevier BV; 2012; 48:1751-1756 10.1016/j.ejca.2012.02.051
• The importance of the lumpectomy surgical margin status in long term results of breast conservation Cite
  Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stockdale FE, et al. The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer. Wiley; 1995; 76:259-267 10.1002/1097-0142(19950715)76:2<259::aid-cncr2820760216>3.0.co;2-2
• Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis Cite
  Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, et al. Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2979-2983 10.1158/1055-9965.epi-09-0607
• Time-varying pattern of recurrence risk for Chinese breast cancer patients Cite
  Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 114:527-535 10.1007/s10549-008-0022-5